Flashlight

DOI: 10.4244/EIJ-D-24-01146

Topaz transjugular transcatheter tricuspid valve replacement

Amr Gamal1, MD, MSc, PhD; Sami Alnasser1, MD; Neil P. Fam1, MD, MSc

A 74-year-old female with severe tricuspid regurgitation (TR), New York Heart Association Class III dyspnoea, oedema, and fatigue was referred for transcatheter tricuspid valve intervention. Past medical history included atrial fibrillation, hypertension and diabetes. Echocardiography demonstrated torrential TR due to a large malcoaptation gap and multiple scallops, with preserved right ventricular function (Figure 1A, Moving image 1). Computed tomography (CT) imaging revealed a tricuspid annular area of 12.7 cm², with significant offset between the inferior vena cava (IVC) and tricuspid annulus, precluding coaxial valve delivery via the femoral approach (Figure 1B). After Heart Team review, she underwent transcatheter tricuspid valve replacement (TTVR) using a 45 mm Topaz device (TRiCares)1 via the transjugular approach. After percutaneous right internal jugular venous access, an Agilis steerable sheath (Abbott) was used to place an extra small SAFARI wire (Boston Scientific) in the apex of the right ventricle (RV), using right coronary wire markers and RV angiography to define the tricuspid annulus (Figure 1C). Under fast pacing, a Topaz 45 mm valve was implanted in a stable position with trace...

Sign in to read
the full article

Forgot your password?
No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Volume 21 Number 20
Oct 20, 2025
Volume 21 Number 20
View full issue


Key metrics

Suggested by Cory

Research correspondence

10.4244/EIJ-D-22-00277 Nov 18, 2022
First-in-human implantation of the Topaz transcatheter tricuspid valve replacement system
Teiger E et al
free

10.4244/EIJV11SWA35 Sep 17, 2015
The tricuspid valve and the right heart: anatomical, pathological and imaging specifications
van Rosendael P et al
free

TRICUSPID VALVE INTERVENTIONS

10.4244/EIJV12SYA32 Sep 18, 2016
Transcatheter interventions for tricuspid regurgitation - heterotopic technology: TricValve
Figulla H et al
free

10.4244/EIJV15I10A159 Nov 15, 2019
The five Ws of transcatheter tricuspid valve repair: Who, What, When, Where, and Why
Williams A et al
free

EXPERT REVIEW

10.4244/EIJ-D-17_00487 Sep 24, 2017
Transcatheter tricuspid valve intervention: state of the art
Taramasso M and Maisano F
free

10.4244/EIJV12SYA28 Sep 18, 2016
Percutaneous interventional options for the treatment of tricuspid regurgitation
Haude M and Prendergast B
free

10.4244/EIJV11SWA37 Sep 17, 2015
Tricuspid valve interventions in 2015
Lauten A and Figulla HR
free

TRICUSPID VALVE INTERVENTIONS

10.4244/EIJV12SYA30 Sep 18, 2016
Transcatheter interventions for tricuspid regurgitation: TriCinch (4Tech)
Rosser B et al
free
Trending articles
202.75

State-of-the-Art

10.4244/EIJ-D-21-00089 Jun 11, 2021
Intracoronary optical coherence tomography: state of the art and future directions
Ali ZA et al
free
47.45

NEW INNOVATION

10.4244/EIJ-D-15-00467 Feb 20, 2018
Design and principle of operation of the HeartMate PHP (percutaneous heart pump)
Van Mieghem NM et al
free
42.15

State-of-the-Art

10.4244/EIJ-D-25-00896 Apr 6, 2026
Pretreatment with antiplatelet agents in patients undergoing coronary revascularisation
Kaur G et al
free
32.2

State-of-the-Art

10.4244/EIJ-D-25-00874 Jun 1, 2026
TAVI and coronary interventions: indications, technical considerations, and clinical scenarios
Aquino Bruno H et al
free
27.6

Original Research

10.4244/EIJ-D-25-01370 May 21, 2026
Prognostic value of early haemodynamic valve deterioration after TAVI
Trimaille A et al
27.6

Original Research

10.4244/EIJ-D-25-01370 Jun 1, 2026
Prognostic value of early haemodynamic valve deterioration after TAVI
Trimaille A et al
19.5

Original Research

10.4244/EIJ-D-26-00032 May 15, 2026
Glucocorticoids to reduce permanent pacemaker implantation after TAVI: the GLUCO-TAVI randomised trial
Fuertes-Kenneally L et al
X

PCR
Impact factor: 9.5
2024 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2025)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2026 Europa Group - All rights reserved